Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world...
-
PHILADELPHIA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT): Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT). The...
-
PHILADELPHIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT): Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT). The...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or...
-
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
-
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
-
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
-
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug